These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

550 related items for PubMed ID: 23072512

  • 1. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.
    Del Mastro L, Lambertini M, Bighin C, Levaggi A, D'Alonzo A, Giraudi S, Pronzato P.
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1391-405. PubMed ID: 23072512
    [Abstract] [Full Text] [Related]

  • 2. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY, Turker I, Aksoy S, Oksuzoglu B, Helvaci K, Yildirim Ozdemir N, Uyeturk U, Uysal Sonmez O, Budakoglu B, Zengin N.
    J BUON; 2013 Nov; 18(3):585-93. PubMed ID: 24065468
    [Abstract] [Full Text] [Related]

  • 3. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A, Smith I.
    Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [Abstract] [Full Text] [Related]

  • 4. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
    Láng I, Bell R, Feng FY, Lopez RI, Jassem J, Semiglazov V, Al-Sakaff N, Heinzmann D, Chang J.
    Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
    [Abstract] [Full Text] [Related]

  • 5. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.
    von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S, GBG 26/BIG 03-05 study group and participating investigators.
    Eur J Cancer; 2011 Oct; 47(15):2273-81. PubMed ID: 21741829
    [Abstract] [Full Text] [Related]

  • 6. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP.
    J Clin Oncol; 2003 Aug 01; 21(15):2889-95. PubMed ID: 12885806
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
    Ardavanis A, Tryfonopoulos D, Orfanos G, Karamouzis M, Scorilas A, Alexopoulos A, Rigatos G.
    Onkologie; 2005 Nov 01; 28(11):558-64. PubMed ID: 16249641
    [Abstract] [Full Text] [Related]

  • 8. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F.
    Breast Cancer Res; 2005 Nov 01; 7(4):R436-43. PubMed ID: 15987448
    [Abstract] [Full Text] [Related]

  • 9. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M.
    Orv Hetil; 2001 Nov 18; 142(46):2563-8. PubMed ID: 11770175
    [Abstract] [Full Text] [Related]

  • 10. Current and future anti-HER2 therapy in breast cancer.
    Vrbic S, Pejcic I, Filipovic S, Kocic B, Vrbic M.
    J BUON; 2013 Nov 18; 18(1):4-16. PubMed ID: 23613383
    [Abstract] [Full Text] [Related]

  • 11. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
    Nishimura R, Okumura Y, Arima N.
    Breast Cancer; 2008 Nov 18; 15(1):57-64. PubMed ID: 18224396
    [Abstract] [Full Text] [Related]

  • 12. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
    Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME, Sugarman S, Ma W, Patil S, Norton L, Hannah AL, Hudis C.
    Clin Cancer Res; 2011 Aug 01; 17(15):5132-9. PubMed ID: 21558407
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL, Kümler I, Palshof JA, Andersson M.
    Breast; 2013 Feb 01; 22(1):1-12. PubMed ID: 23084121
    [Abstract] [Full Text] [Related]

  • 14. [Update: adjuvant trastuzumab in HER2 positive breast cancer].
    Tahover E, Sonnenblick A, Peretz T, Katz D.
    Harefuah; 2012 Jan 01; 151(1):37-42, 61. PubMed ID: 22670500
    [Abstract] [Full Text] [Related]

  • 15. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer.
    Brufsky A, Lembersky B, Schiffman K, Lieberman G, Paton VE.
    Clin Breast Cancer; 2005 Aug 01; 6(3):247-52. PubMed ID: 16137436
    [Abstract] [Full Text] [Related]

  • 16. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
    Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M.
    Breast; 2013 Aug 01; 22 Suppl 2():S152-5. PubMed ID: 24074778
    [Abstract] [Full Text] [Related]

  • 17. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
    Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J.
    J Clin Oncol; 2012 Jul 20; 30(21):2585-92. PubMed ID: 22689807
    [Abstract] [Full Text] [Related]

  • 18. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
    McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, Norton L, Hudis CA.
    Cancer; 2011 Dec 15; 117(24):5461-8. PubMed ID: 21681735
    [Abstract] [Full Text] [Related]

  • 19. Progression and treatment of HER2-positive breast cancer.
    Davoli A, Hocevar BA, Brown TL.
    Cancer Chemother Pharmacol; 2010 Mar 15; 65(4):611-23. PubMed ID: 20087739
    [Abstract] [Full Text] [Related]

  • 20. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    Kiess AP, McArthur HL, Mahoney K, Patil S, Morris PG, Ho A, Hudis CA, McCormick B.
    Cancer; 2012 Apr 15; 118(8):1982-8. PubMed ID: 21887681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.